Sunday, February 7, 2016

Allergan: Wrinkles and New Jersey

Allergan is expanding in New Jersey, with hopes of making more money through Botox and other drugs.

Allergan: Wrinkles and New Jersey

0 comments

Allergan makes glaucoma drugs that are supposed to help the inside of eyes, but it is most famous for fixing the wrinkles around them with Botox.

The company actually has two Botox groups, one that makes the wrinkle products that is a cash (or credit card, more likely) business and not reimbursed by regular health-care insurers, private or public. The other makes drugs for a several parts of the body, from head to bladder, that are generally covered.

Allergan officials were in Bridgewater, N.J. last week to cut the ribbon on a new facility. Sunday's Inquirer story on what went into that choice is here.

The wrinkle sector is about one third of Allergan's business, CEO David Pyott said last week, but gets 80 percent of the attention.

More coverage
More 'PhillyPharma' posts

"To me, it doesn't matter," Pyott said. "Most people would rather read about removing wrinkles."

Philosophically, does America need wrinkle-removing medication when there are other problems?

"I don't find it a dilemma at all," Pyott said. "It would be extremely contentious if the public payer were paying for people's beautification. This is a purely discretionary spend by the consumer, and I think in a good way. When you look at consumers, more and more it is about fitness and physical activity. People realize that feels good."

It helps his corporate cause, of course, but Pyott is proponent of the concept of 60 being the new.....what? 50? 40?

Growing old? No, I'm climbing Mt. Kilimanjaro.

"If you can look like 50, why would you want to look like 60?" said Pyott, noting he was approaching the latter figure. "That's basically what our product does."

Staff Writer
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell Staff Writer
Also on Philly.com:
letter icon Newsletter